IP Group Plc
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- IP Group Plc functions as an early-stage science investment company, concentrating on venture capital and private equity activities from inception through to growth and mature financing stages. The firm is dedicated to cultivating and backing pioneering businesses emerging from universities and leading research institutions. Its investment focus spans key sectors, including life sciences aimed at enhancing human health, deep technology encompassing applied AI, advanced networking, human-machine interfaces, and future computing, alongside clean technology through its Kiko Ventures platform, targeting scalable solutions for climate challenges such as renewable energy and sustainable agriculture. This entity provides significant capital along with crucial strategic guidance, commercial expertise, and operational assistance to its portfolio companies, facilitating the commercialization of intellectual property. IP Group Plc aims to generate capital growth over the long term, supported by cash returns to shareholders, and actively manages exits from its successful ventures. Recent activities include substantial financing rounds for portfolio companies like Artios Pharma and noting potential royalty income from Metsera obesity drug candidates, following its acquisition by Pfizer. The company also completed a significant share buyback program and is targeting over £250 million in exits by 2027, demonstrating its commitment to value realization. Headquartered in London, United Kingdom, since its establishment in 2001, IP Group Plc extends its global reach with offices in locations such as Wilmington, Delaware; Hong Kong; and Melbourne, Australia.
IP Group board may struggle to back sweetened Railpen offer, says Deutsche Bank
Mach42 Completes £7M Funding Round, Led by IP Group With Investment From BGF and Foresight Group
UK's IP Group rebuffs Railpen's revised 71.3 pence proposal
Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside
UK's IP Group gets sweetened takeover offer from top investor Railpen
IP Group rejects Railpen takeover proposal as too low
Deutsche Bank unsurprised by IP Group's rejection of Railpen approach
IP Group rejects takeover approach from its biggest shareholder
IP Group's Istesso starts phase II trial of leramistat in sarcopenia
IP Group portfolio company Enterprise Therapeutics reports positive phase II results in cystic fibrosis
IP Group portfolio company Enterprise Therapeutics reveals positive cystic fibrosis trial results
IP Group appoints former 3i chief as incoming chair
IP Group investee company First Light Fusion raises £25m in fusion energy push
Frontier IP Group's portfolio saw a major funding milestone - ICYMI
IP Group launches Australian cleantech fund with clean energy body
Here's why IP Group looks undervalued. Three brokers take a deep dive
IP Group shares jump 9% as Metsera deal drives return to growth
IP Group returns to growth as Pfizer deal drives NAV rise
IP Group portfolio company Oxa raises $103 million in Series D backed by National Wealth Fund and Nvidia
IP Group portfolio company Microbiotica reports promising trial results in ulcerative colitis